Correction to: Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding(Mol Cell Biochem, (2013), 381, (243–255), 10.1007/s11010-013-1708-5);Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding

Molecular and Cellular Biochemistry

Volumn 381, Issue 1-2, 2013, Pages 243-255

  Rizzo, Roberta ^a   Trentini, Alessandro ^a   Bortolotti, Daria ^a   Manfrinato, Maria C ^a   Rotola, Antonella ^a   Castellazzi, Massimiliano ^a   Melchiorri, Loredana ^a   Di Luca, Dario ^a   Dallocchio, Franco ^a   Fainardi, Enrico ^b   Bellini, Tiziana ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

HLA G; Inflammation; Matrix metalloproteinase; Protein shedding

Indexed keywords

GELATINASE A; GELATINASE B; HLA G ANTIGEN; HLA G1 ANTIGEN; KALININ; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL VIABILITY; CHORIOCARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84882719801     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-024-04996-0     Document Type: Erratum

References (71)

1. Baricordi OR, Stignani M, Melchiorri L, Rizzo R (2008) HLA-G and inflammatory diseases. Inflamm Allergy Drug Targ 7:67-74
2. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N (2003) HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 81:199-252
3. Rouas-Freiss N, Gonçalves RM, Menier C, Dausset J, Carosella ED (1997) Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci USA 94:11520-11525
4. Hunt JS, Petroff MG, McIntire RH, Ober C (2005) HLA-G and immune tolerance in pregnancy. FASEB J 19:681-693
5. Lila N, Carpentier A, Amrein C, Khalil-Daher I, Dausset J, Carosella ED (2000) Implication of HLA-G molecule in heart-graft acceptance. Lancet 355:2138
6. Lila N, Rouas-Freiss N, Dausset J, Carpentier A, Carosella ED (2001) Soluble HLA-G protein secreted by allo-specific CD4 ? T cells suppresses the allo-proliferative response: a CD4? T cell regulatory mechanism. Proc Natl Acad Sci USA 98:12150-12155
7. Créput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N (2003) Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39:587-594
8. Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, Rouas-Freiss N, Durrbach A (2003) Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: possible implications for monitoring patients. Hum Immunol 64:1033-1038
9. Creput C, Durrbach A, Charpentier B, Carosella ED, Rouas-Freiss N (2003) HLA-G: immunoregulatory molecule involved in allograft acceptance. Nephrologie 24:451-456
10. Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED (1998) HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 95:4510-4515
11. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139-10144
12. Rouas-Freiss N, Moreau P, Menier C, Carosella ED (2003) HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 13:325-336
13. LeMaoult J, Rouas-Freiss N, Carosella ED (2005) Immuno-tol-erogenic functions of HLA-G: relevance in transplantation and oncology. Autoimmun Rev 4:503-509
14. Weng PJ, Fu YM, Ding SX, Xu DP, Lin A, Yan WH (2011) Elevation of plasma soluble human leukocyte antigen-G in patients with chronic hepatitis C virus infection. Hum Immunol 72:406-411
15. Fainardi E, Castellazzi M, Stignani M, Morandi F, Sana G, Gonzalez R, Pistoia V, Baricordi OR, Sokal E, Peña J (2011) Emerging topics and new perspectives on HLA-G. Cell Mol Life Sci 68:433-451
16. Fainardi E, Rizzo R, Castellazzi M, Stignani M, Granieri E, Baricordi OR (2009) Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis. Hum Immunol 70:981-987
17. Fainardi E, Rizzo R, Melchiorri L, Stignani M, Castellazzi M, Tamborino C, Paolino E, Tola MR, Granieri E, Baricordi OR (2008) CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing remitting multiple sclerosis. Mult Scler 14:446-454
18. Fainardi E, Rizzo R, Melchiorri L, Stignani M, Castellazzi M, Caniatti ML, Baldi E, Tola MR, Granieri E, Baricordi OR (2007) Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol 192:219-225
19. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Paolino E, Tola MR, Granieri E, Baricordi OR (2006) Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler 12:2-12
20. Fainardi E, Rizzo R, Melchiorri L, Vaghi L, Castellazzi M, Marzola A, Govoni V, Paolino E, Tola MR, Granieri E, Baricordi OR (2003) Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF solubile HLA-I and IL-10 concentrations and MRI findings. J Neuroimmunol 142:149-158
21. Rizzo R, Farina I, Bortolotti D, Galuppi E, Rotola A, Melchiorri L, Ciancio G, Di Luca D, Govoni M (2012) HLA-G may predict the disease course in patients with early rheumatoid arthritis. Hum Immunol doi. doi:10.1016/j.humimm. 2012.11.024
22. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stig-nani M, Carturan S, Ferretti S, Trotta F, Baricordi OR (2006) HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 16:615-623
23. Borghi A, Fogli E, Stignani M, Melchiorri L, Altieri E, Baricordi O, Rizzo R, Virgili A (2008) Soluble human leukocyte antigen-G and interleukin-10 levels in plasma of psoriatic patients: preliminary study on a possible correlation between generalized immune status, treatments and disease. Arch Dermatol Res 300:551-559
24. Shiroishi M, Kuroki K, Rasubala L, Tsumoto K, Kumagai I, Kurimoto E, Kato K, Kohda D, Maenaka K (2006) Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 (LILRB2/LIR2/ILT4/CD85d). Proc Natl Acad Sci USA 103:16412-16417
25. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan C, Dunbar R, Ogg GS, Cerundolo V, Rolink A (1998) Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 160:3096-3100
26. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML (1997) A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7:273-282
27. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M (1997) A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186:1809-1818
28. Ponte M, Cantoni C, Biassoni R, Tradori-Cappai A, Bentivoglio G, Vitale C, Bertone S, Moretta A, Moretta L, Mingari MC (1999) Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA 96:5674-5679
29. Rajagopalan S, Long EO (1999) A human histocompatibility leucocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189:1093-1099
30. + cells by interacting with CD8. J Immunol 164:6100-6104
31. Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, Zhang X, Li W, Wang S, Dong Z (2011) Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci 102:1272-1280
32. Marchal-Bras-Goncalves R, Rouas-Freiss N, Connan F, Choppin J, Dausset J, Carosella ED, Kirszenbaum M, Guillet J (2001) A soluble HLA-G protein that inhibits natural killer cell-mediated cytotoxicity. Transplant Proc 33:2355-2359
33. Liang S, Ristich V, Arase H, Dausset J, Carosella ED, Horuzsko A (2008) Modulation of dendritic cell differentiation by HLA-G and ILT4 requires the IL-6-STAT3 signaling pathway. Proc Natl Acad Sci USA 105:8357-8362
34. Gregori S, Tomasoni D, Pacciani V, Scirpoli M, Battaglia M, Magnani CF, Hauben E, Roncarolo MG (2010) Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 116:935-944
35. Kapasi K, Albert SE, Yie S, Zavazava N, Librach CL (2000) HLA-G has a concentration-dependent effect on the generation of an allo-CTL response. Immunology 101:191-200
36. Ishitani A, Geraghty D (1992) Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. proc natl acad sci usa 89:3947-3951
37. Park GM, Lee S, Park B, Kim E, Shin J, Cho K, Ahn K (2004) Soluble HLA-G generated by proteolytic shedding inhibits NK-mediated cell lysis. Biochem Biophys Res Commun 313:606-611
38. Dong Y, Lieskovska J, Kedrin D, Porcelli S, Mandelboim O, Bushkin Y (2003) Soluble nonclassical HLA generated by the metalloproteinase pathway. Human Immunol 64:802-810
39. 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem 269:6689-6694
40. Zidi I, Guillard C, Marcou C, Krawice-Radanne I, Sangrouber D, Rouas-Freiss N, Carosella ED, Moreau P (2006) Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers. Cell Mol Life Sci 63:2669-2681
41. Carey BW, Kim DY, Kovacs DM (2007) Presinilin/c-secretase and a-secretase-like peptidases cleave human MHC class I proteins. Biochem J 401:121-127
42. Massova I, Kotra LP, Fridman R, Mobashery S (1998) Matrix metalloproteinases: structures, evolution, and diversification. FASEB J 12:1075-1095
43. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metallopro-teinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8:221-233
44. Hernández-Pérez M, Mahalingam M (2012) Matrix metallopro-teinases in health and disease: insights from dermatopathology. Am J Dermatopathol 34:565-579
45. Choi S, Kim JY, Park JH, Lee ST, Han IO, Oh ES (2012) The matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells. Biochem Biophys Res Commun 417:1260-1264
46. Fainardi E, Castellazzi M, Tamborino C, Trentini A, Manfrinato MC, Baldi E, Tola MR, Dallocchio F, Granieri E, Bellini T (2009) Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis. Mult Scler 15:547-554
47. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, CasettaI, Paolino E, Granieri E, Dallocchio F(2006) Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 12:294-301
48. Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA (2011) Serum matrix metallopro-teinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 21:569-578
49. Manicone AM, McGuire JK (2008) Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19:34-41
50. Opdenakker G, Van Den Steen PE, Van Damme J (2001) Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol 22:571-579
51. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289:1202-1206
52. van der Meer A, Lukassen HG, van Lierop MJ, Wijnands F, Mosselman S, Braat DD, Joosten I (2004) Membrane-bound HLA-G activates proliferation and interferon-gamma production by uterine natural killer cells. Mol Hum Reprod 10:189-191
53. Polakova K, Russ G (2000) Expression of the non classical HLA-G antigen in tumor cell lines is extremely restricted. Neoplasma 47:342-348
54. Malagutti N, Aimoni C, Balboni A, Stignani M, Melchiorri L, Borin M, Pastore A, Rizzo R, Baricordi OR (2008) Decreased production of human leukocyte antigen G molecules in sinonasal polyposis. Am J Rhinol 22:468-473
55. Kobayashi K, Matsumoto S, Morishima T, Kawabe T, Okamoto T (2000) Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression. Cancer Res 60:3978-3984
56. Ongaro A, Stignani M, Pellati A, Melchiorri L, Massari L, Caruso G, De Mattei M, Caruso A, Baricordi OR, Rizzo R (2010) Human leukocyte antigen-G molecules are constitutively expressed by synovial fibroblasts and upmodulated in osteoarthritis. Hum Immunol 71:342-350
57. Yao YQ, Barlow DH, Sargent IL (2005) Differential expression of alternatively spliced transcripts of HLA-G in human preim-plantation embryos and inner cell masses. J Immunol 175:8379-8385
58. Park B, Oh H, Lee S, Song Y, Shin J, Sung YC, Hwang SY, Ahn K (2002) The MHC class I homolog of human cytomegalovirus is resistant to down-regulation mediated by the unique short region protein (US)2, US3, US6, and US11 gene products. J Immunol 168:3464-3469
59. Bellini T, Trentini A, Manfrinato MC, Tamborino C, Volta CA, Di Foggia V, Fainardi E, Dallocchio F, Castellazzi M (2012) Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms. J Biochem 151:493-499
60. Velvizhi R, Prabir K (1996) Western blot of proteins from Coo-massie-stained polyacrylamide gels. Anal Biochem 234:102-104
61. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW (2002) A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 277:4485-4491
62. Verspurten J, Gevaert K, Declercq W, Vandenabeele P (2009) Site predicting the cleavage of proteinase substrates. Trends Biochem Sci 34:319-323
63. Zhao L, Teklemariam T, Hantash BM (2012) Reassessment of HLA-G isoform specificity of MEM-G/9 and 4H84 monoclonal antibodies. Tissue Antigens 80:231-238
64. Riteau B, Rouas-Freiss N, Menier C, Paul P, Dausset J, Carosella ED (2001) HLA-G2, -G3, and -G4 isoforms expressed as non-mature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol 166:5018-5026
65. Rebmann V, Busemann A, Lindemann M, Grosse-Wilde H (2003) Detection of HLA-G5 secreting cells. Hum Immunol 64:1017-1024
66. Kridel SJ, Chen E, kotra LP, Howard EW, Mobashery S, Smith JW (2001) Substrate hydrolysis by matrix metalloproteinase-9. J Biological Chem 276:20572-20578
67. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V (1997) Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 277:225-228
68. Diaz-Lagares A, Alegre E, LeMaoult J, Carosella ED, Gonzalez A (2008) Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu. Immunology 126:436-445
69. Ghorpade A, Persidskaia R, Suryadevara R, Che M, Jaun Liu X, Persidsky Y, Gendelman HE (2001) Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-association dementia. J Virol 75:6572-6583
70. Newby AC (2008) Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability. Arteroscler Thromb Vasc Biol 28:2108-2114
71. Webster NL, Crowe SM (2006) Matrix meralloproteinase, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 80:1052-1066